alexa Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia.
Ophthalmology

Ophthalmology

Journal of Clinical & Experimental Ophthalmology

Author(s): Hosseini H, Nejabat M, Khalili MR

Abstract Share this page

Abstract In the last two decades of angiogenesis research, a variety of angiogenic regulators have been identified. The discovery of several antiangiogenic factors has led to the development of novel ophthalmic therapies. Pterygia are characterized by the encroachment of a fleshy fibrovascular tissue from the bulbar conjunctiva onto the cornea. The pathogenesis of pterygia is presently uncertain and its treatment is quiet controversial. It has also been postulated that the development of pterygia depends on a changed angiogenic stimulator-to-inhibitor ratio. On of the most important known mediators of angiogenesis in pterygia is vascular endothelial growth factor (VEGF). In this article, we briefly review the evidences supporting involvement of vascular endothelial growth factor (VEGF) in the pathogenesis of pterygia and then based on these evidences, we hypothesize that local application of bevacizumab, a monoclonal antibody against VEGF, may inhibit neovascularization and thus, may stop the progression or prevent the recurrence of pterygia. This article was published in Med Hypotheses and referenced in Journal of Clinical & Experimental Ophthalmology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords